Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the PDGFRA/MEK/ERK signaling pathway

Fig. 5

Valtrate elicits anti-glioblastoma activity through inhibition of the PDGFRA/MEK/ERK signaling pathway. A–B Pathway enrichment analysis of the RNA-Seq data from valtrate-treated U251 and GBM#P3 cells. C Western blot to detect levels of proteins involved in PI3K/AKT and MEK/ERK signaling pathways in U251, LN229 and GBM#P3 after treatment with different concentrations of valtrate. D–E Cell viability determined with the CCK-8 assay for U251 and GBM#P3 cells under valtrate treatment in the presence of the ERK1/2 activator t-butylhydroquinone (tBHQ). U251: 2 μΜ valtrate; GBM#P3: 1 μΜ valtrate; and 50 μM tBHQ. F–G Quantitative analysis of EdU assays performed on U251 and LN229 under the conditions indicated, under valtrate treatment with or without the activator of ERK tBHQ. U251: 2 μΜ valtrate; LN229: 2 μΜ valtrate; and tBHQ: 50 μM. H–I Percentage of apoptotic U251 and GBM#P3 cells under the conditions indicated, under valtrate treatment with or without tBHQ. U251: 2 μΜ valtrate, GBM#P3: 1 μΜ valtrate; and tBHQ: 50 μM. J–K Quantification of transwell cell numbers for U251 and LN229 under the conditions indicated, under valtrate treatment with or without tBHQ. U251: 2 μΜ valtrate; LN229: 2 μΜ valtrate; and tBHQ: 50 μM). L Western blot to detect the levels of mitochondrial apoptosis- and EMT-related proteins in U251 and GBM#P3 cells with the valtrate or tBHQ treated. U251: 2 μΜ valtrate; GBM#P3: 1 μΜ valtrate; and tBHQ: 50 μM. Data are shown as the mean ± SD and the differences between groups were analyzed with the Student’s t-test. n.s none significant, *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page